Switching from systemic to the topical carbonic anhydrase inhibitor dorzolamide: Effect on the quality of life of glaucoma patients with drug-related side effects

Israel Medical Association Journal

Volumn 5, Issue 4, 2003, Pages 260-263

  Nesher, Ronit ^a,c   Ticho, Uriel ^b,d  

^a MEIR MEDICAL CENTER   (Israel)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

^d HEBREW UNIVERSITY   (Israel)

Author keywords

Carbonic anhydrase inhibitors; Dorzolamide; Glaucoma; Health assessment questionnaire; Quality of life

Indexed keywords

DRUG PRODUCTS; PATIENT MONITORING; PATIENT REHABILITATION;

GLAUCOMA PATIENTS;

PATIENT TREATMENT;

ACETAZOLAMIDE; ANTIGLAUCOMA AGENT; CARBONATE DEHYDRATASE INHIBITOR; DORZOLAMIDE; METHAZOLAMIDE;

ABDOMINAL DISCOMFORT; ADULT; AGED; ARTICLE; BITTER TASTE; CARBONATED BEVERAGE; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONSULTATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG RECHALLENGE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; DYSPNEA; ENERGY CONSUMPTION; EPIGASTRIC PAIN; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MALE; MEDICAL ASSESSMENT; MENTAL HEALTH; MYALGIA; NAUSEA; NUTRITIONAL INTOLERANCE; OPEN ANGLE GLAUCOMA; PARESTHESIA; PHYSICAL PERFORMANCE; PROSPECTIVE STUDY; QUALITY OF LIFE; QUESTIONNAIRE; SCORING SYSTEM; SIDE EFFECT; SOCIAL INTERACTION; TREATMENT OUTCOME; VERTIGO; VISUAL IMPAIRMENT; WELLBEING;

AGED; CARBONIC ANHYDRASE INHIBITORS; FEMALE; GLAUCOMA; GLAUCOMA, OPEN-ANGLE; HEALTH STATUS INDICATORS; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; OCULAR HYPERTENSION; PROSPECTIVE STUDIES; QUALITY OF LIFE; SULFONAMIDES; THIOPHENES;

EID: 0038134974     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Epstein DL, Grant WM. Carbonic anhydrase inhibitor side effects. Arch Ophthalmol 1977;95:1378-82.
2. Sugrue MF, Harris A, Adamsons I. Dorzolamide hydrochloride: A topically active, carbonic anhydrase inhibitor for the treatment of glaucoma. Drugs Today 1997;33:283-98.
3. Keisu M, Wiholm BE, Ost A, Mortimer O. Acetazolamide-associated aplastic anemia. J Intern Med 1990;228:627-32.
4. Centofanti M, Manni GL, Napoli D, Bucci MG. Comparative effects of intraocular pressure between systemic and topical carbonic anhydrase inhibitors. A clinically masked, crossover study. Pharmacol Res 1997;35:481-5.
5. Hutzelmann JE, Polis AB, Michael AJ, Adamsons IA. A comparison of the efficacy and tolerability of dorzolamide and acetazolamide as adjunctive therapy to timolol. Acta Ophthalmol Scand 1998;76:717-22.
6. Steward AL, Hays RD, Ware JE Jr. The MOS Short form General Health Survey. Reliability and validity in a patient population. Med Care 1988;26:724-35.
7. Ware JE Jr, Snow K, Kosinski M, et al. SF 36 Health Survey. Manual and Interpretation Guide. Boston: The Health Institute, New England Medical Center, 1993.
8. Pfeiffer N. Dorzolamide: Development and clinical application of a topical carbonic anhydrase inhibitor. Surv Ophthalmol 1997;42:137-51.
9. Strahlman E, Tipping R, Vogel R. A six-week dose-response study of the ocular hypotensive effect of dorzolamide with one-year extension. Am J Ophthalmol 1997;122:183-94.
10. McHorney CA, Ware JE, Raczek AE. The MOS 36 item short form health survey II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 1993;31:247-63.
11. Garrat AM, Ruta DA, Abdalla LI, et al. The SF-36 Health profile. An outcome measure suitable for routine use within the NHS. Br Med J 1993;306:1440-4.
12. Jenkinson C, Coulter A, Wright L. The short form (SF-36) Health Survey Questionnaire normative data for adults of working age. Br Med J 1993;306:1437-40.
13. Hurst NP, Ruta DA, Kind P. Comparison of the MOS short form - 12(SF12) health status questionnaire with the SF36 in patients with rheumatoid arthritis. Br J Rheumatol 1998;37:862-9.
14. Lawrence K, McWhinnie D, Jenkinson C, Coulter A. Quality of life in patients undergoing inguinal hernia repair. Ann R Coll Surg 1997;79:40-5.
15. Brenner MG, Curbow G, Javitt JC, et al. Vision change and quality of life in the elderly: Response to cataract surgery and treatment of other chronic ocular conditions. Arch Ophthalmol 1993;111:680-5.
16. Legro MW. Quality of life and cataracts. A review of patient centered studies of cataract surgery outcomes. Ophthalmic Surg 1991;22:431-43.
17. Cassard SD, Patrick DL, Damiano AM. Reproducibility and responsiveness of the VF-14, an index of functional impairment in patients with cataracts. Arch Ophthalmol 1995;113:1508-13.
18. Steinberg EP, Tielsch JM, Schein OD. The VF-14: An index of functional impairment in patients with cataract. Arch Ophthalmol 1994;112:195-203.
19. Scott IU, Schein OD, West S, Bandeen-Roche K, Enger C, Folstein F. Functional status and quality of life measurement among ophthalmic patients. Arch Ophthalmol 1994;112:329-35.
20. Ross JE, Bron AJ, Clarke DD. Contrast sensitivity and visual disability in chronic simple glaucoma. Br J Ophthalmol 1984;68:821-7.
21. Mills RP, Drance SM. Esterman disability rating in severe glaucoma. Ophthalmology 1986;93:371-8.
22. Parrish II RK, Gedde SJ, Scott IU, et al. Visual function and quality of life among patients with glaucoma. Arch Ophthalmol 1997;115:1447-55.
23. Barber BL, Santanello NC. Relating spontaneous adverse experience reports to scores on a questionnaire querying tolerability. Int J Clin Pharmacol Ther 1995;33:598-604.
24. Barber BL, Strahlman ER, Laibovitz R, Guess HA, Reines SA. Validation of a questionnaire for comparing the tolerability of ophthalmic medications. Ophthalmology 1997;104:334-42.
25. Strohmaier K, Snyder E, Adamsons I. A multicenter study comparing dorzolamide and pilocarpine as adjunctive therapy to timolol: Patient preference and impact on daily life. J Am Optom Assoc 1998;69:441-51.